prothrombin schematic published by Davie and Kulman.1 Note:
Prethrombin-2a is equivalent to prethrombin-2 minus the 13 amino acid
N-terminal of the A-chain. Prothrombin (72 kDa) Meizothrombin (72
kDa) Fragment 1.2 (30 kDa) Thrombin (42 kDa) -thrombin (40
high citrate conditions; 29, 30 however, other researchers assert that
impurities, such as FX, play key roles in the activation.28, 32 While low
concentrations of sodium citrate yield minimal activation of
prothrombin, concentrations of 25% (weight/volume
from the complementary DNA sequence. Proc Natl Acad Sci USA
1988;85:1412- 1416 (published erratum appears in Proc Natl Acad USA
1988;85: 5056). 23. Funk C, Funk LB, Kennedy M, Pong A, FitzGerald GA:
Human platelet/erythroleukemia cell PGG/H synthase: eDNA
T. Miralles J, Palomaki E. Vapaatalo H: Effects of peri-operatively
administered diclofenac and indomethacin on blood loss, bleeding time
and plasma prostanoids in man. Eur 1 Anaesthesiol1989; 6:335-342.
126. Daykin D. Janson P, McMahon L: Ethanol potenti
evaluation of a disposable device for performing simultaneous duplicate
bleeding time determinations. Am 1 Clin Pathol1978: 70:406-408. 48.
Burns ER: The hemalet bleeding time device. Lab Med 1986;17:745-747.
49. Smith C: Surgicutt: A device for modified
Pett SB, Alonso D, Richter RC, Stelzer P, Subramanian V, Tack-Goldman K,
Gay WA Jr: Differential inhibition by aspirin of vascular and platelet
prostaglandin synthesis in atherosclerotic patients. N EngiJ Med 1983;
308:800-805. 32. FitzGerald GA. Oates JA
Abstract Thrombin is the key serine protease in hemostasis because it is
responsible for activating both procoagulant proteins critical for
creating fibrin clots and anticoagulant proteins needed to return the
system to balance. Prothrombin is converted t
1828. 95. Flordal P A, Sahlin S: Use of desmopressin to prevent bleeding
complications in patients treated with aspirin. Br 1 Surg 1993;80: 723724. 96. Ferraris VA, Swanson E: Aspirin usage and perioperative blood
loss in patients undergoing unexpected op
1970;213:2049-2053. 107. Rumack CM, Guggenheim MA, Rumack BH,
Peterson RG, Johnson ML, Braithwaite WR: Neonatal intracranial
hemorrhage Downloaded from jcp.sagepub.com by guest on May 25,
2011 EFFECTS OF NSAIDS ON PLATELET FUNCTION AND SYSTEMIC
Hemostatic efficacy of a fibrin sealant-based topical agent in a femoral
artery injury model: a randomized, blinded, placebo-controlled study.
J.Vasc.Surg. 26, 274 (1997). 90. Lord, S.T. Expression of a cloned human
fibrinogen cDNA in Escherichia coli: sy
from the aspirin component of the ongoing Physicians' Health Study. N
Eng/ 1 Med 1988;318:262-264. 86. Peto R. Gray R, Collins R. Wheatley
K, Hennekens C, Jamrozik K, Warlow C, Hafner B, Thompson E, Norton S,
Gilliland J, Doll R: Randomised trial of proph
fibrinolytics, in Loscalzo J, Dzau VJ, Creager MA (eds.): Vascular
Medicine. Boston: Little, Brown and Company, 1992;659-682. 61.
O'Grady J, Moncada S: Aspirin: a paradoxical effect on bleeding time
(letter). Lancel1978: 2:780. 62. Rajah SM. Penny A, Kest
cycle-oxygenase inhibition: Relationship between inhibition of
thromboxane production and the plasma unbound concentration of
S(+)-ibuprofen. Br 1 Clin Pharmacal 1991;31:131- 138. 77. Williams K,
Day R, Knihinicki R, Duffield A: The stereoselective uptake
Xia, H. Fibrinogen biosynthesis. Assembly, intracellular degradation, and
association with lipid synthesis and secretion. Ann N Y Acad Sci 936,
480-495 (2001). 22. Clark, R.A. Fibrin is a many splendored thing. J
Invest Dermatol 121, xxi-xxii (2003). 23.
endto-end crosslinking of gamma chains by factor XIIIa. Proc Natl Acad
Sci U S A 95, 537-541 (1998). 39. Yee, V.C. et al. Three-dimensional
structure of a transglutaminase: human blood coagulation factor XIII.
Proc Natl Acad Sci U S A 91, 7296-7300 (1994)
Thr287 creating prothrombin-2a from prethrombin-2 and -thrombin
from meizothrombin or FIIa. 9 Figure 2.1. Schematic of the amino acid
sequence of prepro-prothrombin. Preproprothrombin contains a signal
peptide, propeptide, Gla domain, two Kringle domains
of ibuprofen, tolmetin and placebo on the gastric mucosa of aspirinsensitive volunteers. Am 1 Gastroenterol1979; 72:528-534. tt6. Caruso I.
Bianchi Porro G: Gastroscopic evaluation of antiinflammatory agents. Br
Med /1980;280:75-78. t t 7. Lanza FL: Endos
Holmes Gl, Kohl H, Lee RB, Reynolds N, Schmid FR. Tsao C: Effects of
diflunisal on platelet function and fecal blood loss. Clin Pharmacal Ther
1981;30:378-384. 68. Rane A, Oelz 0, Frolich JC, Seyberth HW.
Sweetman BJ, Watson JT, Wilkinson GR. Oates JA: Re
O'Laughlin JC, Hoftiezer JW, Mahoney JP, Ivey KJ: Does aspirin prolong
bleeding from gastric biopsies in man? Gaslroinlest Endose 1981;27:1-5.
55. Weiss HJ, Aledort LM, Kochwa S: The effects of salicylates on the
hemostatic properties of platelet in man.J
and basis for specificity of transglutaminase-catalyzed epsilon-(gammaglutamyl) lysine bond formation. Adv Enzymol Relat Areas Mol Biol 54,
1-56 (1983). 34. Collet, J.P. et al. The alphaC domains of fibrinogen
affect the structure of the fibrin clot, its
K.F. et al. Functional analysis of fibrin cfw_gamma-chain cross-linking by
activated factor XIII: determination of a cross-linking pattern that
maximizes clot stiffness. Blood 110, 902-907 (2007). 55. Standeven, K.F.
et al. Functional analysis of fibrin g
complexes and a model of their structure. J Clin Invest 66, 1033-1043
(1980). 60. Muller, M.F., Ris, H. & Ferry, J.D. Electron microscopy of fine
fibrin clots and fine and coarse fibrin films. Observations of fibers in
cross-section and in deformed states
by aspirin. Arteriosclerosis 1983; 3:383-388. 41. Born GVR, Cross MJ:
The aggregation of blood platelets./ Physiol1963;168:178-195. 42.
Harker LA. Slichter SJ: The bleeding time as a screening test for
evaluation of platelet function. N EngiJ Med 1972: 28
cascade is activated, prothrombin is converted to FIIa by the
prothrombinase complex which consists of FXa, activated Factor V
(FVa), and calcium ions complexed on the phospholipid surface of
activated platelets. 9, 13, 14 This complex converts prothrombi
Asp99 and Ser205 which is located in a cleft within the B-domain18, 19
and brought into close proximity by salt bridges following activation.19
The active site is surrounded by three surface loops19-21 and two
charged surface areas (exosites)11 that creat